Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HSCT for Pediatric and AYA High-Risk Solid Tumors
NCT04530487Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Ewing sarcoma, neuroblastoma, rhabdomyosarcoma (RMS) and 3 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Transplant-Related Mortality at 30 days and Rate of Grade III or Higher Organ Toxicity at 30 days. Started Aug 2020; status: terminated.
02
Conditions
Ewing sarcomaneuroblastomarhabdomyosarcoma (RMS)desmoplastic small round cell tumor (DSRCT)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT04530487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530487.